Compare INTS & GTIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTS | GTIM |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.7M |
| IPO Year | 2021 | 2013 |
| Metric | INTS | GTIM |
|---|---|---|
| Price | $4.03 | $1.51 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 31.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $142,315,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.29 |
| Revenue Growth | N/A | ★ 3.01 |
| 52 Week Low | $0.22 | $1.10 |
| 52 Week High | $8.06 | $2.09 |
| Indicator | INTS | GTIM |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 50.96 |
| Support Level | $3.51 | $1.44 |
| Resistance Level | $5.00 | $1.52 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 30.08 | 46.43 |
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.